Metastatic lung cancer kills >180,000 people in the United States annually and only ~10% of patients with lung adenocarcinoma (LUAD) have targetable driver genomic alterations. There remains an unmet need for innovative therapies. BRMS1 is a metastasis suppressor gene that is decreased in LUAD and is associated with increased cancer migration, invasion, and poor prognosis. Mutations in DNA binding domain (DBD) of p53 are common in LUAD and are associated with increased metastases. We have made a novel observation that BRMS1 functions as transcription factor for selected metastasis-related genes in p53mut but not p53WT LUAD. Specifically, we show that BRMS1 binds promoter regions containing active p53 responsive elements to transcriptionally regulate metastasis-related genes, Maspin and Serpine1, in p53mut but not p53WT LUAD. Moreover, we demonstrate that BRMS1 expression is related to biologically distinct histologic subtypes of LUAD and that restoration of BRMS1 using the CK2 inhibitor CX4945 results in significantly less cell migration and invasion in p53mut compared with p53WT LUAD. Our overarching goal is to determine the importance of maintaining BRMS1 in the context of p53 mutations using clinically relevant, human LUAD samples, patient-derived organoids (PDO), and conditional GEMM models.
Two Specific Aims will test our hypotheses:
Aim 1) Identify downstream targets and associated components of BRMS1-mediated transcription in p53mut LUAD. We will use ChIP-seq to identify genome-wide specific BRMS1-DNA binding regions in p53mut LUAD cells. We will then determine the functional significance of BRMS1-DNA binding on transcriptional regulation by performing RNA-seq in BRMS1WT and BRMS1KO LUAD isogenic cells with different p53 status. Next, using shRNA screens combined with reporter gene assays to characterize gene-specific components, we test the hypothesis that BRMS1 differentially regulates transcription via interaction with unique transcription co-factors in p53mut LUAD.
Aim 2) Determine the requirement for BRMS1 in regulating metastases in human p53mut LUAD. We will leverage our extensive, clinically-annotated biorepository of >2000 human LUAD specimens with varying p53 mutational profiles, pathologic stages, and histologic subtypes to characterize the spectrum of LUAD tumors. We then examine the efficacy of the CK2 inhibitor, CX4945, in preventing BRMS1 degradation and decreasing metastases in specific histological subtypes of LUAD using our newly developed LUAD patient-derived organoid (PDO) model of metastases. We use this PDO model modified with an inducible expression system to assess the importance of maspin, and serpine1 on BRMS1-mediated metastasis suppression. Finally, using our newly created Brms1-/-/KrasG12D GEMM with intratracheal delivery of p53mut CRISPR we create a metastatic LUAD mouse model to assess the requirement of BRMS1 for CX4945- mediated suppression of metastases. Impact: Our work will provide mechanistic and translational evidence to support future clinical trials that target BRMS1 in p53mut LUAD with biologically distinct histologic subtypes.
Metastatic lung cancer kills over 180,000 people in the United States annually and there remains an unmet need for innovative therapies. We have identified that BRMS1, a gene that decreases lung cancer metastases, is important in lung adenocarcinomas with specific mutations and histologies. The goals of this research are to identify ways to increase BRMS1 expression in lung adenocarcinoma, decrease development of metastases, and, ultimately, save lives.
|Bucciarelli, Peter R; Tan, Kay See; Chudgar, Neel P et al. (2018) BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol 13:73-84|
|Qu, Yang; Emoto, Katsura; Eguchi, Takashi et al. (2018) Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. J Thorac Oncol :|
|Brandt, Whitney S; Yan, Wanpu; Zhou, Jian et al. (2018) Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis. J Thorac Cardiovasc Surg :|